Phase 2 Ovarian Cancer Trial, Recruiting NCT04520139 Sponsor: University of California, Irvine Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT04520139
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who have gone through menopause (either naturally, with no periods for 12 months, or due to surgical removal of the ovaries)
  • People who have been diagnosed through a tissue or pathology test with stage III or IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  • People whose general physical health and ability to carry out daily activities meets a certain minimum level, based on a standard medical scale (confirm with trial site)
  • People with a life expectancy of more than one year
  • People who have already had surgery to remove as much of the cancer as possible, or who are planned to have that surgery after starting chemotherapy
  • People who have been prescribed at least six cycles of a platinum-based chemotherapy treatment
  • People whose blood counts, liver function, and kidney function meet certain minimum levels as assessed by the trial site (confirm with trial site)

Who may not be able to join:

  • People who have had any other type of cancer in the past, except for certain common skin cancers
  • People who have received chemotherapy, radiation therapy, or a red blood cell-stimulating drug within the last 6 months
  • People with a history of severe head injury
  • People who have been diagnosed with dementia or another condition affecting the brain and nervous system over time
  • People with severe depression or other serious mental health conditions that have not responded to treatment
  • People with cancer that is known to have spread to the brain
  • People currently dealing with an active infection that requires treatment
  • People with a known disease that weakens the immune system
  • People with active autoimmune diseases, such as lupus, where the immune system attacks the body
  • People currently receiving medications that suppress the immune system
  • People with a known diagnosis of HIV, hepatitis B, or hepatitis C
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Daniela Bota, MD, PhD, Chao Family Comprehensive Cancer Center

Phone: 1-877-827-7883

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of California, Irvine
Registry
ClinicalTrials.gov
Start date
21 May 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum Tolerated Dose of N-Acetyl-Cysteine in Ovarian Cancer Patients Receiving Platinum-Based Therapy; Recommended Phase 2 Dose for NAC administered with PBT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov